Assessment of Glutathione Level in Non-Alcoholic Fatty Liver Disease Patients

Glutathione level & NAFLD

  • Y. Pavan Kumar Reddy Associate Professor, Department of Gastroenterology, Sapthagiri institute of medical sciences and research center, Bangalore, India
  • Suraj Uppalapati Assistant Professor, Department of Gastroenterology, Sapthagiri institute of medical sciences and research center, Bangalore, India https://orcid.org/0000-0001-8164-0381
Keywords: Alanine transaminase, fatty liver, Glutathione

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a range of hepatic disorders associated with fatty deposits in liver, which occur in the absence of alcohol consumption or alcohol abuse. NAFLD. The present study assessed glutathione level in non-alcoholic fatty liver disease patients. Subjects and Methods: The present study was conducted in Department of Internal Medicine, Narayana Medical College & Hospital, Chintareddy Palem, Nellore, Andhra Pradesh. Duration of the study was from February 2018 to January 2019. 40 patients of NAFLD and 20 cases of fatty liver disease were recruited. Serum levels of 8-OHdG were measured using the highly sensitive 8-OHdG Check enzyme-linked immunosorbent assay (ELISA). Serum levels of GGT were measured using the Qualigent® GGT kit. Serum levels of glutathione (GSH) were measured using the GSH kit. Results: The mean total bilirubin in group I was 1.2 mg/dL and in group II was 0.7 mg/dL, aspartate transaminase was 58.2 U/l in group I and 62.6 U/l in group II, alanine transaminase in group I was 142.4 U/l in group I and 128.2 U/l in group II, alkaline phosphatase was 284.2 U/l in group I and 302.4 U/l in group II and γ-glutamyltranspeptidase in group I was 98.2 U/l and 118.4 U// in group II. The difference was non- significant (P> 0.05). The mean glutathione level in group I was 0.6 and in group II was 0.4 and which increased to 1.4 in group I and 1.2 in group II after 3 months. The difference within the group found to be significant (P< 0.05). Conclusion: Authors found that there was reduction in alanine transaminase, glutathione and gamma-glutamyltranspeptidase level. Antioxidant therapy with glutathione may reduce the pathological oxidative stress in the liver in NASH, preventing the progression from NAFLD to NASH cases.

Downloads

Download data is not yet available.

References

Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical impli- cations. Hepatol. 2010;51(2):679–689. Available from: https://dx.doi.org/10.1002/hep.23280.

Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients. 2013;5(5):1544–1560. Available from: https://dx.doi.org/10.3390/nu5051544.

Wagner LBV, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Ther Adv Gastroenterol. 2011;4(4):249–263. Available from: https://dx.doi.org/10.1177/1756283x11403809.

Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24(5):695– 708. Available from: https://dx.doi.org/10.1016/j.bpg.2010.08.005.

Floyd RA, West MS, Eneff KL, Hogsett WE, Tingey DT. Hydroxyl free radical mediated formation of 8- hydroxyguanine in isolated DNA. Arch Biochem Biophys. 1988;262(1):266–272. Available from: https://dx.doi.org/10.1016/0003-9861(88)90188-9.

Ore A, Akinloye OA. Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non- Alcoholic Fatty Liver Disease. Medicina. 2019;55(2):26–26. Available from: https://dx.doi.org/10.3390/medicina55020026.

Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, et al. Insulin Resistance Accelerates a Dietary Rat Model of Nonalcoholic Steatohepatitis. Gastroenterology. 2007;132(1):282–293. Available from: https://dx.doi.org/10.1053/j.gastro.2006.10.014.

Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59–69. Available from: https://dx.doi.org/10.1016/j.freeradbiomed.2011.10.003.

Irie M, Sohda T, Anan A, Fukunaga A, Takata K, Tanaka T. Reduced Glutathione suppresses Oxidative Stress inNonalco- holic Fatty Liver Disease. Euroasian J Hepatogastroenterol. 2016;6(1):13–18. Available from: https://dx.doi.org/10.5005/jp-journals-10018-1159.

Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev. 2018;2018:9547613–9547613. Available from: https://dx.doi.org/10.1155/2018/9547613.

Day CP, James OFW. Steatohepatitis: A tale of two “hits”? Gastroenterol. 1998;114(4):842–845. Available from: https://dx.doi.org/10.1016/s0016-5085(98)70599-2.

Angulo P. Nonalcoholic Fatty Liver Disease. N Eng J Med. 2002;346(16):1221–1231. Available from: https://dx.doi.org/10.1056/nejmra011775

Published
2020-05-18
How to Cite
Y. Pavan Kumar Reddy, & Suraj Uppalapati. (2020). Assessment of Glutathione Level in Non-Alcoholic Fatty Liver Disease Patients. Academia Journal of Medicine, 3(1), 19-22. https://doi.org/10.47008/ajm.2020.3.1.5